The Trump administration’s new drug policy prioritizes focus on border security and law enforcement. This approach deviates from past efforts, which have focused on a patient and healthcare-centric approach to combating the opioid epidemic. “To meet the urgent need of this moment, the Trump administration is launching an unprecedented whole-of-government effort to stop these drugs […]
More patients with opioid use disorder (OUD) are turning to extended-release buprenorphine to treat their substance use than ever before. However, prescription use of non-extended release formulations has declined, according to a Massachusetts-focused study published in JAMA Network Open. Throughout the state, men were also more likely to be prescribed the extended-release version than women. […]
Fewer than one in five Medicare patients with a substance use disorder (SUD) receive medication-assisted-treatment (MAT), including popular options such as buprenorphine and methadone, to treat their condition. Still, the number of providers prescribing buprenorphine for Medicare beneficiaries rose by 32% in 2023. This is according to a new report from the U.S. Department of […]
HC Jones, Inc., branded as Jones, disclosed raising $9 million of a $10.2 million equity funding round. The New York City-based digital nicotine cessation company offers a nicotine lozenge delivery service and an AI-powered app that includes supportive content, progress tracking and connections to a community of Jones users. It couches its service and products […]
This is an exclusive BHB+ story While addressing the opioid crisis is often hailed as a bipartisan priority, the Trump administration’s sweeping reforms to mental health and substance use disorders (SUD) funding reveal a significant shift in America’s approach to these challenges. The new administration has focused its efforts on cracking down on illegal fentanyl […]
Twenty-eight million adults in the U.S. have alcohol use disorder (AUD), and the life-threatening condition particularly impacts Medicaid populations. Despite the existence of evidence-based medications for AUD, less than half of all Medicaid managed care plans cover all types of medications for AUD, according to a new study published in JAMA Network Open. “The results […]
The Trump administration’s drastic government workforce cuts may impact the substance use disorder (SUD) industry, and lawmakers are pushing back. The Substance Abuse and Mental Health Services Administration (SAMHSA), the federal organization that regulates and funds several aspects of the behavioral health industry, has already experienced a workforce cut – and may be facing far […]
As the opioid epidemic approaches its second decade of devastating impact, some health care providers are integrating evidence-based research into their clinical practice to combat this persistent crisis. Nonprofit substance use disorder (SUD) provider Caron Treatment Centers has taken the approach of integrating research into care. Caron’s Chief Medical Officer, Adam Scioli, said having research […]
Substance use disorder (SUD) treatment provider Ark Behavioral Health is permanently closing one of its locations and laying off facility staff, according to publicly available documents. Ark cited “unanticipated and unprecedented decline” in patient census, the company’s inability to renegotiate its lease, get a credit extension or otherwise raise money as reasons for closing the […]
More evidence has emerged to support GLP-1 medications’ potential as alcohol use disorder (AUD) treatment tools. Few medications are available to treat AUD, and the use of the drugs is often “overshadowed” by other critical substance use disorder (SUD) trends. GLP-1s, the weight loss drugs sweeping the nation, could reduce alcohol use, according to a […]
By continuing to use the site, you agree to the use of cookies. more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
